A focus on innovation is critical to any medical device business. Over the past few years, the Neurovascular business of Covidien has experienced significant growth. A key part of that growth is due to the ability to identify, develop, and launch innovative products. The leaders from Covidien will share insights and strategies on how they successfully identified and commercialized new early-stage treatments, and put internal programs in place to create a culture conducive to innovation.
John Liedtky – VP of Global Marketing, Covidien
Earl Slee – VP of R&D, Strategy, and Business Development, Covidien
Earl Slee, Covidien Neurovascular Vice President of Research & Development, Strategy and Business Development, joined Micro Therapeutics Inc. (MTI) in April 1998 as Vice President, Research and Development. In 2006, MTI became a fully owned subsidiary of ev3. In 2010, ev3 became a fully owned subsidiary of Covidien. From August 1995 until 1998, Earl was Vice President Research and Development with Aequitron Medical, Inc., a manufacturer of portable respiratory care devices in Plymouth, MN. From June 1992 until August 1995, he was Director of Engineering with Instromedix, a manufacturer of portable EKG monitors in Hillsboro, OR. From 1978 to 1992, Earl held various engineering and management positions with Pfizer, Welch Allyn and Hughes Aircraft Co. Earl holds an M.B.A. from the Tuck School of Business, Dartmouth College, an MSEE from San Diego State University, and a B.A. in Physics from the University of California, San Diego.
Brett Wall – President, Covidien Vascular Therapies, Neurovascular and International
Brett Wall, President of Covidien Vascular Therapies, Neurovascular and International, is responsible for development, manufacturing and global marketing for the company’s Neurovascular division, as well as sales for the U.S. and Europe. Brett joined Covidien following the company’s acquisition of ev3 in 2010. He served as Vice-President of Marketing for both the Peripheral Vascular and Neurovascular Divisions, then transitioned to lead the ev3 International business, and most recently, Covidien Vascular Therapies International. Prior to joining ev3, Brett held various global positions including Senior Director of MicroTherapeutics and Director of Cardiovascular Marketing in the Asia Pacific region for Boston Scientific. Brett holds a degree in Business Administration from the University of Nebraska at Kearney.
Tom Whalen, VP of Operations, Covidien
Stacey Pugh, Sr. Director of Clinical Research, Covidien
5:30 – 6:00pm Registration and Networking (Light refreshments and appetizers will be provided).
6:00 – 7:15pm Presentation
7:15 – 7:30pm Q&A